$0.50
1.02% yesterday
Nasdaq, Sep 18, 10:06 pm CET
ISIN
US09609G1004
Symbol
BLUE
Sector
Industry

bluebird bio, Inc. Stock price

$0.50
-0.20 28.46% 1M
-0.95 65.63% 6M
-0.89 64.13% YTD
-2.70 84.48% 1Y
-11.14 95.74% 3Y
-69.06 99.29% 5Y
-22.81 97.88% 10Y
Nasdaq, Closing price Wed, Sep 18 2024
-0.01 1.02%
ISIN
US09609G1004
Symbol
BLUE
Sector
Industry

Key metrics

Market capitalization $96.39m
Enterprise Value $298.68m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.54
P/S ratio (TTM) P/S ratio 2.11
P/B ratio (TTM) P/B ratio 0.74
Revenue growth (TTM) Revenue growth 1,032.60%
Revenue (TTM) Revenue $45.69m
EBIT (operating result TTM) EBIT $-336.00m
Free Cash Flow (TTM) Free Cash Flow $-228.82m
Cash position $212.05m
EPS (TTM) EPS $-2.39
P/E forward negative
P/S forward 1.02
EV/Sales forward 3.15
Short interest 27.35%
Show more

Is bluebird bio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

bluebird bio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a bluebird bio, Inc. forecast:

3x Buy
30%
6x Hold
60%
1x Sell
10%

Analyst Opinions

10 Analysts have issued a bluebird bio, Inc. forecast:

Buy
30%
Hold
60%
Sell
10%

Financial data from bluebird bio, Inc.

Assets
Mar '24
272 272
Cash 212 212
Claims 0.97 0.97
Inventories 30 30
Other current assets Other current assets Current assets 28 28
360 360
Property, plant and equipment 286 286
Financial assets - -
Intangible Assets 16 16
Other fixed assets Other assets Fixed assets 58 58
Total Assets 631 631
Liabilities
Mar '24
Equity 131 131
500 500
Current liabilities 294 294
Non-current liabilities 207 207
Total Capital 631 631

In millions USD.

Don't miss a Thing! We will send you all news about bluebird bio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

bluebird bio, Inc. Stock News

Positive
24/7 Wall Street
2 days ago
There's a trade that's generally accepted anytime someone makes an investment.
Neutral
Business Wire
5 days ago
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has completed the restatement of its consolidated financial statements for the year ended December 31, 2022, and for each of the first three quarters of 2022 and 2023. Today, the Company filed its Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”), including the rest...
Positive
Seeking Alpha
22 days ago
Investment activity in July focused on Business Development Companies, with $2,000 added to the market. Adjusted dividend income in July of $709, up 19% Y/Y and down 4% sequentially. Main picks included Blackstone Secured Lending, Ares Capital and Owl Rock Capital.
More bluebird bio, Inc. News

Company Profile

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

Head office United States
CEO Andrew Obenshain
Employees 375
Founded 1992
Website www.bluebirdbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today